 Digoxin Immune Fab therapy management digitalis intoxication safety efficacy results observational surveillance study observational surveillance study safety effectiveness treatment Digoxin Immune Fab Ovine Digibind patients digitalis intoxication April limited number patients treatment digoxin-specific Fab fragments multicenter clinical trial commercial availability July study additional clinical data treatment week follow-up study adults Digoxin Immune Fab Ovine patients equal years old developed toxicity maintenance digoxin Fifty percent patients complete response treatment partial response response response patients uncertain patients confidence interval allergic reaction digoxin-specific antibody fragments history allergy antibiotic drugs patients confidence interval recrudescent toxicity Risk recrudescent toxicity dose antibody total patients experienced posttreatment adverse events events patients manifestations underlying disease unrelated Fab treatment Digoxin-specific antibody fragments effective patients physicians life-threatening digitalis intoxication